Genetics and therapy of familial hypercholesterolemia

de Sauvage Nolting, P.R.W.

Citation for published version (APA):
Dear Dr. Roberts,

We do greatly appreciate the opportunity to modify our manuscript according to your instructions and adapt it into a seriously shortened and improved version.

We, however, would like to ask whether a full (but modified) manuscript might be given consideration by yourself.

We hope this is not too audacious but since the Heart Protection Study used 40 mg simvastatin versus 80 in our study and LDL reductions were only 27% versus 48% in our trial, we feel our data are novel and in fact a nice next step after the HPS results.

Ours is truly the first study in this regard, especially considering its follow-up of two years.

We look forward to your opinion in this regards.

Sincerely yours,

Pernette R.W. de Sauvege Nolting
Academic Medical Center, G1-114
Meibergdreef 9
1105 AZ Amsterdam, the Netherlands
Tel:+31205662824
Fax:+31206916972

On behalf of,

Meibergdreef 9 Postbus 22660 1100 DD Amsterdam Telefoon (020) 566 9111 Fax (020) 566 4440
March 4, 2002

P.R.W. de Sauvage Nolting, MD
Department of Vascular Medicine, Gl-114
Academic Medical Center
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands

MS#: 2020094
MS.Title: Two-Year Efficacy and Safety of Simvastatin 80 mg in Familial Hypercholesterolemia

Dear Dr. de Sauvage Nolting:

Watson and Crick won a Nobel Prize with a Letter-to-the-editor. Your manuscript fits very nicely into the BRIEF REPORT format.

Sorry,

William C. Roberts, MD

Baylou University Medical Center, Wadley Tower 457, 3600 Gaston Avenue, Dallas, TX 75246
Phone: 214-826-8252 Fax: 214-826-2855 Email: ajc@baylorl Dallas.edu